NEIMETH INTERNATIONAL PHARMACEUTICALS PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.85 NGN | 0.00% |
|
0.00% | -4.64% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,347 | 1,177 | 4,235 | 3,324 | 2,716 | 8,290 |
| Enterprise Value (EV) 1 | 2,125 | 2,056 | 5,825 | 4,344 | 5,913 | 10,342 |
| P/E ratio | 7.32 x | 5.35 x | 19.9 x | 12.3 x | -8.36 x | -3.21 x |
| Yield | - | - | 2.91% | 4% | - | - |
| Capitalization / Revenue | 0.59 x | 0.5 x | 1.49 x | 1.09 x | 0.93 x | 3.75 x |
| EV / Revenue | 0.94 x | 0.87 x | 2.05 x | 1.43 x | 2.03 x | 4.68 x |
| EV / EBITDA | 5.79 x | 3.76 x | 8.42 x | 6.62 x | 61.6 x | -19.1 x |
| EV / FCF | 66.7 x | -70.2 x | -10.6 x | -26.4 x | - | -25.6 x |
| FCF Yield | 1.5% | -1.42% | -9.48% | -3.79% | - | -3.91% |
| Price to Book | 1.37 x | 1.1 x | 3.32 x | 2.35 x | 3.49 x | 5.02 x |
| Nbr of stocks (in thousands) | 1,899,157 | 1,899,157 | 1,899,157 | 1,899,157 | 1,899,157 | 4,273,105 |
| Reference price 2 | 0.7091 | 0.6200 | 2.230 | 1.750 | 1.430 | 1.940 |
| Announcement Date | 18/12/18 | 23/12/19 | 30/12/20 | 29/12/21 | 31/03/23 | 31/01/24 |
1NGN in Million2NGN
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 2,269 | 2,371 | 2,839 | 3,047 | 2,919 | 2,210 |
| EBITDA 1 | 366.8 | 547.6 | 691.8 | 656.7 | 96.02 | -541.7 |
| EBIT 1 | 265 | 444.1 | 581.1 | 548.7 | -12.39 | -619.4 |
| Operating Margin | 11.68% | 18.73% | 20.47% | 18.01% | -0.42% | -28.03% |
| Earnings before Tax (EBT) 1 | 202.5 | 304.4 | 297.4 | 365.3 | -310.4 | -2,581 |
| Net income 1 | 184 | 220.1 | 212.5 | 270.6 | -325 | -2,581 |
| Net margin | 8.11% | 9.28% | 7.48% | 8.88% | -11.13% | -116.79% |
| EPS 2 | 0.0969 | 0.1159 | 0.1119 | 0.1425 | -0.1711 | -0.6039 |
| Free Cash Flow 1 | 31.83 | -29.3 | -552.1 | -164.8 | - | -404.1 |
| FCF margin | 1.4% | -1.24% | -19.45% | -5.41% | - | -18.29% |
| FCF Conversion (EBITDA) | 8.68% | - | - | - | - | - |
| FCF Conversion (Net income) | 17.3% | - | - | - | - | - |
| Dividend per Share | - | - | 0.0650 | 0.0700 | - | - |
| Announcement Date | 18/12/18 | 23/12/19 | 30/12/20 | 29/12/21 | 31/03/23 | 31/01/24 |
1NGN in Million2NGN
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 778 | 879 | 1,590 | 1,021 | 3,197 | 2,052 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.121 x | 1.605 x | 2.298 x | 1.554 x | 33.3 x | -3.788 x |
| Free Cash Flow 1 | 31.8 | -29.3 | -552 | -165 | - | -404 |
| ROE (net income / shareholders' equity) | 20.6% | 22.8% | 18.1% | 20.1% | - | -212% |
| ROA (Net income/ Total Assets) | 7.22% | 11% | 7.9% | 5.41% | - | -4.97% |
| Assets 1 | 2,549 | 2,008 | 2,690 | 5,001 | - | 51,941 |
| Book Value Per Share 2 | 0.5200 | 0.5600 | 0.6700 | 0.7400 | 0.4100 | 0.3900 |
| Cash Flow per Share 2 | 0.0200 | 0.0600 | 1.390 | 1.070 | 0.2400 | 0.5000 |
| Capex 1 | 188 | 151 | 603 | 344 | 1,270 | 891 |
| Capex / Sales | 8.31% | 6.36% | 21.24% | 11.29% | 43.49% | 40.32% |
| Announcement Date | 18/12/18 | 23/12/19 | 30/12/20 | 29/12/21 | 31/03/23 | 31/01/24 |
1NGN in Million2NGN
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
1.85
NGN
Average target price
1.75
NGN
Spread / Average Target
-5.41%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.64% | 5.18M | |
| +32.63% | 694B | |
| +29.39% | 593B | |
| -1.65% | 371B | |
| +20.09% | 331B | |
| +6.65% | 290B | |
| +14.08% | 239B | |
| -3.11% | 209B | |
| +9.97% | 209B | |
| +8.16% | 169B |
- Stock Market
- Equities
- NEIMETH Stock
- Financials Neimeth International Pharmaceuticals Plc
